(S)-(7-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol | 187543-81-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: (S)-(7-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol
• 英文别名: [(3S)-6-bromo-2,3-dihydro-1,4-benzodioxin-3-yl]methanol
• CAS: 187543-81-3
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: FJGPKNZNSQTEAL-ZETCQYMHSA-N

物化性质

• 沸点：
  333.4±42.0 °C(Predicted)
• 密度：
  1.600±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-(7-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol 在 氢氧化钾 、 potassium permanganate 作用下， 生成
  参考文献：
  名称：

  Total synthesis and antifungal activity of 9-methoxystrobilurin L as the originally proposed 1,4-Benzodioxan structure

  摘要：

  Total synthesis of both enantiomers of 9-methoxystrobilurin L as the originally proposed 1,4-benzodioxan structure was successfully achieved. The H-1 and C-13 NMR spectra of synthesized 9-methoxystrobilurin L were compared with those of a naturally-occurring sample. lt was strongly indicated that naturally-occurring 9-methoxystrobilurin L has not the originally reported 1,4-benzodioxan structure but a 1,5-benzodioxepin structure, the same as previously reported 9-methoxystrobilurin K. Antifungal activities of the synthesized compounds toward several typical fungi were also examined, and they were less active than 9-methoxystrobilurin K. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00561-3
• 作为产物：
  描述：

  5-bromo-2-[(2S)-oxiran-2-ylmethoxy]phenyl formate 在 乙酸乙酯 、 水 、 magnesium sulfate 、 EtOAc isooctane 作用下， 以 sodium hydroxide 为溶剂， 反应 1.5h， 以to give the title compound (4.9 g)的产率得到(S)-(7-bromo-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol
  参考文献：
  名称：

  MODULATORS OF DOPAMINE NEUROTRANSMISSION

  摘要：

  本发明涉及一种新颖的1-(2,3-二氢-1,4-苯并二氧杂环-2-基)-甲胺衍生物，可用作多巴胺神经递质的调节剂，更具体地说，可用作多巴胺能稳定剂。在其他方面，本发明涉及将这些化合物用于治疗方法以及包含本发明化合物的制药组合物。

  公开号：

  US20110105462A1

文献信息

• NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20150336943A1

  公开（公告）日：2015-11-26

  The present invention concerns benzodioxane-piperidine with general formula I: wherein notably: R1 represents one or more identical or different substituent(s) on the benzene ring, each independently representing a hydrogen or halogen atom, or a C 1-4 alkyl group, or a C 1-4 alkoxy group or a C 1-4 hydroxyalkyl group or a C 1-4 alkylcarbonyl or an alkoxycarbonyl group or an OH group or an SO2R group with R alkyl, or a CN group, or a CF3 group, or an OCF 3 group; n=1, 2 or 3; m=0 or 1, and R2 represents one or more identical or different substituent(s) on the oxazolidinone or morpholinone ring, each independently representing: a hydrogen atom, a C 1-4 alkyl group, or a C 1-4 alkoxy group, or a C 1-4 hydroxyalkyl group, or an alkylcarbonyl group, or an alkoxycarbonyl group, or an alkoxyphenyl group.

  本发明涉及具有通式I的苯二氧杂环戊二酮： 其中特别地： R1代表苯环上一个或多个相同或不同的取代基，每个独立地代表氢或卤素原子，或C1-4烷基，或C1-4烷氧基，或C1-4羟基烷基，或C1-4烷基羰基，或烷氧羰基，或OH基，或SO2R基，其中R是烷基，或CN基，或CF3基，或O 基； n=1, 2或3； m=0或1，以及 R2代表噁唑烷酮或吗啉酮环上一个或多个相同或不同的取代基，每个独立地代表： 氢原子，C1-4烷基，或C1-4烷氧基，或C1-4羟基烷基，或烷基羰基，或烷氧羰基，或烷氧基苯基。
• [EN] MODULATORS OF DOPAMINE NEUROTRANSMISSION<br/>[FR] MODULATEURS DE LA NEUROTRANSMISSION DE LA DOPAMINE
  申请人：NSAB AF NEUROSEARCH SWEDEN AB

  公开号：WO2009133109A1

  公开（公告）日：2009-11-05

  The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

  这项发明涉及新颖的1-(2,3-二氢-1,4-苯并二氧杂环戊烷-2-基)-甲胺衍生物，用作多巴胺神经传导调节剂，更具体地用作多巴胺稳定剂。在其他方面，该发明涉及将这些化合物用于治疗方法以及包括该发明化合物的药物组合物。
• Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine
  作者：Deyu Kong、Shimeng Guo、Yushe Yang、Bin Guo、Xin Xie、Wenhao Hu

  DOI：10.1016/j.bmcl.2019.01.014

  日期：2019.3

  somewhat pharmacokinetic and/or safety issues. Herein, we describe the identification of 2,3-dihydrobenzo[b][1,4]dioxine as a novel scaffold for FFA1 agonists. Comprehensive structure-activity relationship study based on this scaffold led to the discovery of (S)-3-(4-(((S)-7-(4-methoxyphenyl)-2,3-dihydrobenzo [b][1,4]dioxin-2-yl)methoxy) phenyl)hex-4-ynoic acid (26k), which displayed a potent FFA1 agonistic

  FFA1（游离脂肪酸受体1）已成为一种有吸引力的抗糖尿病靶标，因为它在低血糖风险低的胰腺β细胞中介导葡萄糖刺激的胰岛素分泌的增强作用。许多报道的FFA1激动剂具有一定的药代动力学和/或安全性问题。在这里，我们描述了2,3-二氢苯并[b] [1,4]二恶英作为FFA1激动剂的新型支架的鉴定。基于这种支架的全面的构效关系研究导致发现了（S）-3-（4-（（（（S）-7-（4-methoxyphenyl）-2,3-dihydrobenzo] [b] [1,4 ]二恶英-2-基）甲氧基）苯基）己基-4-炔酸（26k），它显示出强大的FFA1激动活性和良好的药代动力学特征。随后的体内研究表明，化合物26k可显着改善ICR小鼠的葡萄糖耐量。总之，
• [EN] DOPAMINE D2 RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RÉCEPTEURS DOPAMINERGIQUES D2
  申请人：BROAD INST INC

  公开号：WO2016100940A1

  公开（公告）日：2016-06-23

  The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

  本发明涉及新型多巴胺D2受体配体。该发明进一步涉及功能偏向的多巴胺D2受体配体以及利用这些化合物治疗或预防与多巴胺活性失调相关的中枢神经系统和全身性疾病。本发明涉及调节多巴胺D2受体的新型化合物。具体而言，本发明的化合物在多巴胺D2受体上显示功能选择性，并在D2受体下游、0-阿雷斯汀途径和/或cAMP途径上表现出选择性。
• Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles
  作者：Bin Guo、Shimeng Guo、Jing Huang、Jingya Li、Jia Li、Qian Chen、Xianli Zhou、Xin Xie、Yushe Yang

  DOI：10.1016/j.bmc.2018.10.019

  日期：2018.12

  novel series of fused-ring phenyl propanoic acid analogues were designed. Comprehensive structure-activity relationship studies around novel scaffolds were conducted and led to several analogues exhibited potent GPR40 agonistic activities and high selectivity against other fatty acid receptors. Further evaluation of pharmacokinetic (PK) profiles and in vivo efficacy identified compound 40a with excellent

  由于GPR40介导低血糖风险低的胰腺β细胞中葡萄糖刺激的胰岛素分泌的增强作用，因此它已成为治疗糖尿病的新的潜在治疗靶标。为了扩大化学空间并鉴定具有改善的肝脏安全性的结构不同的GPR40激动剂，设计了一系列新的稠环苯基丙酸类似物。围绕新型支架进行了全面的构效关系研究，并导致几种类似物表现出有效的GPR40激动活性和对其他脂肪酸受体的高选择性。药代动力学（PK）谱和体内功效的进一步评估确定了化合物40a在口服葡萄糖耐量试验期间具有出色的PK特性和显着的降糖功效。另外，化合物40a显示出较低的肝胆转运蛋白抑制作用和良好的可药物性。所有结果表明，化合物40a是有希望的进一步开发的候选物。